Intervention

LDK378

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting0

Common conditions6

Lead sponsors shown2

Clinical trials

9 shown

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.NCT02450903 · 2015-08-21

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerNCT02276027 · 2015-01-20

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibNCT02040870 · 2014-03-07

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementNCT01964157 · 2013-09-01

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung CancerNCT01772797 · 2013-06-01

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerNCT01685138 · 2012-12-20

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and CrizotinibNCT01685060 · 2012-11-26

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma KinaseNCT01283516 · 2011-01-24

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLCNCT01947608

NO_LONGER_AVAILABLE

Common conditions

Non-small Cell Lung Cancer4 Non-small Cell Lung Cancer (NSCLC)2 Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1 Anaplastic Lymphoma Kinase (ALK)1 Non-Small-Cell Lung Cancer1 Tumors Characterized by Genetic Abnormalities of ALK1

Leading sponsors

Novartis Pharmaceuticals8 Yonsei University1

Trial status mix

COMPLETED8

NO_LONGER_AVAILABLE1

Phase mix

PHASE26

PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.